Panacea Biotec DuPont analysis

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Per cent unless marked ×

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

5-step DuPont — ROE = tax burden × interest burden × EBIT margin × turnover × leverage						FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	0.86×	0.97×	1.10×	−1.01×	−2.64×
	0.34×	0.20×	0.13×	−0.03×	−0.09×
	−4.5%	−5.9%	−10.9%	−10.2%	−29.8%
	0.50×	0.50×	0.44×	0.45×	0.30×
	1.52×	1.52×	1.55×	1.48×	1.51×
	−1.0%	−0.9%	−1.1%	−0.2%	−3.3%
	−0.6%	−0.6%	−1.0%	−0.1%	−4.0%

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

PANACEABIO₹329.05

Panacea Biotec Limited

· Pharma & Health

₹ CrorePeersSAIPARENT HIKAL INDOCO DCAL WINDLAS HESTERBIO SOLARA SYNCOMFMcap ₹2,017 Cr

Profitability Growth Credit Liquidity Working Capital Yield Analysis DuPont

Ratios — % unless marked × 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
5-Step DuPont — ROE = Tax Burden × Interest Burden × EBIT Margin × Turnover × Leverage
Tax Burden (Net Income/Pretax) ×	-2.64	-1.01	1.10	0.97	0.86
Interest Burden (Pretax/EBIT) ×	-0.09	-0.03	0.13	0.20	0.34
EBIT Margin %	-29.80	-10.15	-10.86	-5.90	-4.52
Asset Turnover ×	0.30	0.45	0.44	0.50	0.50
Financial Leverage (Assets/Equity) ×	1.51	1.48	1.55	1.52	1.52
ROE (5-step product, year-end total equity) %	-3.33	-0.18	-1.07	-0.85	-1.01
ROE (owners' profit / average owners' equity) %	-3.99	-0.14	-1.00	-0.64	-0.64

No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.